- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Português (Portugal)
- Polski
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
BioCryst Pharmaceuticals Inc (BCRX)
BioCryst Pharmaceuticals Inc stock price live, this page displays NASDAQ BCRX stock exchange data. View the BCRX premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the BioCryst Pharmaceuticals Inc real time stock price chart below.
What Is the BioCryst Pharmaceuticals Inc Stock Price Today?
The BioCryst Pharmaceuticals Inc stock price today is 8.350.
What Is the Stock Symbol for BioCryst Pharmaceuticals Inc?
The stock symbol for BioCryst Pharmaceuticals Inc is ""BCRX.""
What Stock Exchange Does BioCryst Pharmaceuticals Inc Trade On?
BioCryst Pharmaceuticals Inc is listed and trades on the NASDAQ stock exchange.
Is BioCryst Pharmaceuticals Inc a Good Stock to Buy?
Determining whether BioCryst Pharmaceuticals Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the BCRX quote. (ISIN: US09058V1035)
What Is the BioCryst Pharmaceuticals Inc Stock Price Today?
The BioCryst Pharmaceuticals Inc stock price today is 8.350.
What Is the Stock Symbol for BioCryst Pharmaceuticals Inc?
The stock symbol for BioCryst Pharmaceuticals Inc is ""BCRX.""
What Stock Exchange Does BioCryst Pharmaceuticals Inc Trade On?
BioCryst Pharmaceuticals Inc is listed and trades on the NASDAQ stock exchange.
Is BioCryst Pharmaceuticals Inc a Good Stock to Buy?
Determining whether BioCryst Pharmaceuticals Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the BCRX quote. (ISIN: US09058V1035)
Fair Value
An estimate of a BioCryst's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
8.220
8.400
52 wk Range
6.015
11.310
BCRX Scorecard
Full Analysis
Net income is expected to grow this year
BCRX is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a BioCryst's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
8.2208.400
52 wk Range
6.01511.310
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
BCRX Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a BioCryst's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Price Target
16.727
Upside
+100.33%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
2 analysts have revised their earnings downwards for the upcoming period
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Buy
BioCryst Pharmaceuticals Inc Company Profile
BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and injectable protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX17725, a protein therapeutic for netherton syndrome which is in phase 1; Avoralstat, an ocular plasma kallikrein inhibitor for diabetic macular edema that is in preclinical phase; and BCX10013, an oral Factor D inhibitor for complement-mediated diseases, as well as developing Oral C5 Inhibitor and Oral C2 Inhibitor. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Shionogi & Co., Ltd., Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.
BioCryst Pharmaceuticals Inc SWOT Analysis
Orladeyo's Triumph | BioCryst's oral HAE treatment Orladeyo drives impressive revenue growth, with projected peak annual sales exceeding $1 billion and expanding market share |
Pediatric Potential | Explore BioCryst's pursuit of Orladeyo's pediatric expansion, a $100 million-plus opportunity not yet factored into current peak sales guidance |
Pipeline Progress | Delve into BioCryst's diversification efforts, including promising developments in Netherton Syndrome and Diabetic Macular Edema treatments |
Financial Trajectory | Analysts project full-year profitability by 2026, with price targets ranging from $8 to $20, reflecting optimism in BioCryst's growth potential |
BioCryst Pharmaceuticals Inc Earnings Call Summary for Q2/2025
- BioCryst reports Q2 2025 EPS of $0.15, beating $0.01 forecast; revenue reaches $163.4M, up 45% YoY; stock surges 13.84% pre-market
- Company pays down $125M in debt, strengthens financial position; projects full-year revenue of $580-600M, expecting upper half of range
- Orlodayo drives growth; CEO targets $1B peak sales and market leadership; focus on rare disease assets and licensing opportunities
- Upcoming milestones include Pediatric Orlodayo granules PDUFA in Dec 2025; analysts expect profitability this year
- Management confident in maintaining market leadership despite new HAE competitors; exploring pipeline opportunities in Netherton Syndrome and DME
Last Updated: 04/08/2025, 14:36
Read Full TranscriptCompare BCRX to Peers and Sector
Metrics to compare | BCRX | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipBCRXPeersSector | |
|---|---|---|---|---|
P/E Ratio | −48.2x | −0.4x | −0.5x | |
PEG Ratio | −0.64 | −0.01 | 0.00 | |
Price/Book | −3.8x | 3.2x | 2.6x | |
Price / LTM Sales | 3.1x | 5.5x | 3.3x | |
Upside (Analyst Target) | 82.9% | 311.5% | 42.9% | |
Fair Value Upside | Unlock | 20.6% | 6.2% | Unlock |
Analyst Ratings
10 Buy
1 Hold
0 Sell
Ratings:
11 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 16.727
(+100.33% Upside)
Earnings
Latest Release
Aug 04, 2025
EPS / Forecast
0.15 / 0.01
Revenue / Forecast
163.35M / 149.82M
People Also Watch
FAQ
What Stock Exchange Does BioCryst Trade On?
BioCryst is listed and trades on the Nasdaq Stock Exchange stock exchange.
What Is the Stock Symbol for BioCryst?
The stock symbol for BioCryst is "BCRX."
What Is the BioCryst Market Cap?
As of today, BioCryst market cap is 1.72B.
What Is BioCryst's Earnings Per Share (TTM)?
The BioCryst EPS (TTM) is -0.17.
When Is the Next BioCryst Earnings Date?
BioCryst will release its next earnings report on 28 Oct 2025.
From a Technical Analysis Perspective, Is BCRX a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
How Many Times Has BioCryst Stock Split?
BioCryst has split 0 times.
How Many Employees Does BioCryst Have?
BioCryst has 580 employees.
What is the current trading status of BioCryst (BCRX)?
As of 12 Aug 2025, BioCryst (BCRX) is trading at a price of 8.35, with a previous close of 8.20. The stock has fluctuated within a day range of 8.22 to 8.40, while its 52-week range spans from 6.02 to 11.31.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.